Ankilozan Spondilitli Hastalarda Etanercept Tedavisinin Etkinliği ve Güvenilirliği+
Yükleniyor...
Dosyalar
Tarih
2010
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi Tıp Fakültesi Dergisi
Erişim Hakkı
Attribution 3.0 United States
Özet
Bu çalışmanın amacı; ankilozan spondilit (AS)’li hastalarda etanercept tedavisinin etkinliğini ve güvenilirliğini araştırmaktır.
Gereç ve Yöntem: 21 AS’li hasta tedavi öncesi ve 6 aylık tedaviden sonra klinik ve laboratuvar parametrelerle değerlendirildi. Tedavinin etkinliği ayrıca Uluslararası AS Çalışma Grubu (ASAS)’nun AS’te tedaviye yanıt kriterleri olan ASAS-20, ASAS-40, ASAS-5/6, ASAS parsiyel remisyon ve BASDAI-50 yanıtı ile belirlendi.
Bulgular: 6 aylık etanercept tedavisinden sonra klinik ve laboratuvar değerlendirme parametrelerinin tümünde istatistiksel olarak anlamlı iyileşme görüldü. Ayrıca 18 hastada ASAS-20, 16 hastada ASAS-40, 14 hastada ASAS-5/6, 10 hastada ASAS parsiyel remisyon ve 16 hastada BASDAI-50 yanıtları elde edildi. Ciddi yan etki nedeni ile tedaviyi bırakmak zorunda kalan hasta olmadı. 4 hastada enjeksiyon yeri reaksiyonu, 1 hastada eritem, 1 hastada bulantı-kusma şikayeti tespit edildi.
Sonuç: Bulgularımız, etanercept tedavisinin AS’li hastalarda etkili olduğunu ve güvenle kullanılabileceğini göstermektedir.
The aim of this study was to evaluate efficacy and safety of etanercept in patients with ankylosing spondylitis (AS). Material and Methods: 21 patients with AS were evaluated before and after 6 months of etanercept treatment based on the clinical and laboratory parameters. Clinical efficacy was determined using criteria defined by the asessment in AS (ASAS) International Working Group (ASAS-20 ASAS-40, ASAS-5/6, and ASAS partial remission) and BASDAI-50 responses. Results: There were statistically significant improvements in all clinical and laboratory parameters after the six months of etanercept treatment (p <0.001). Additionally, ASAS-20 was achieved in 18 of 21 patients. ASAS-40, ASAS-5/6, ASAS partial remission and BASDAI-50 were achieved in 16, 13, 10 and 16 patients, respectively. None of the patients withdrew from etanercept treatment because of serious adverse effect. Injection site reaction in 4, erythema in 1, and nausea and vomiting in 1 patients were observed throughout of the study. Conclusion: Our results demonstrated that etanercept treatment was safe and effective in AS patients.
The aim of this study was to evaluate efficacy and safety of etanercept in patients with ankylosing spondylitis (AS). Material and Methods: 21 patients with AS were evaluated before and after 6 months of etanercept treatment based on the clinical and laboratory parameters. Clinical efficacy was determined using criteria defined by the asessment in AS (ASAS) International Working Group (ASAS-20 ASAS-40, ASAS-5/6, and ASAS partial remission) and BASDAI-50 responses. Results: There were statistically significant improvements in all clinical and laboratory parameters after the six months of etanercept treatment (p <0.001). Additionally, ASAS-20 was achieved in 18 of 21 patients. ASAS-40, ASAS-5/6, ASAS partial remission and BASDAI-50 were achieved in 16, 13, 10 and 16 patients, respectively. None of the patients withdrew from etanercept treatment because of serious adverse effect. Injection site reaction in 4, erythema in 1, and nausea and vomiting in 1 patients were observed throughout of the study. Conclusion: Our results demonstrated that etanercept treatment was safe and effective in AS patients.
Açıklama
İnönü Üniversitesi Tıp Fakültesi Dergisi 17 (2) 91-96 (2010)
Anahtar Kelimeler
Etanercept, Ankilozan Spondilit, Etkinlik, Güvenilirlik, Etanercept, Ankylosing Spondylitis, Efficacy
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Kalı, Gökhan ;Ersoy, Yüksel ;Durmuş, Bekir ;Altay, Zuhal ;Baysal, Özlem ;Ersoy, Yasemin ;(2010) Ankilozan Spondilitli Hastalarda Etanercept Tedavisinin Etkinliği ve Güvenilirliği+İnönü Üniversitesi Tıp Fakültesi Dergisi.
